Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 23–Aug 30, 2026)
Here’s what’s on the biotech calendar for August 23–August 30: 2 FDA decision dates, 4 trial catalysts, and 1 earnings reports from tracked companies.
💊 FDA Decisions (PDUFA Dates)
| Date | Ticker | Drug | Indication | Type |
|---|---|---|---|---|
| 2026-08-25 | JAZZ | — | sBLA | |
| 2026-08-25 | ZYME | — | adults with previously treated | NDA |
🧪 Trial Catalysts & Milestones
- OSTX — 2026-08-25: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Meta
- OSTX — 2026-08-26: Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
- ARV — 2026-08-26: Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
- OSTX — 2026-08-30: LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
📊 Earnings This Week
- ARTV — 2026-08-27 (est. EPS -0.6375)
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- ORIC — Phase 1, Phase 2 — Recruiting in 9 days, score 60/100
- SNDX — Phase 2 — Active Trial in 9 days, score 60/100
- CORT — Phase 2 — Recruiting in 9 days, score 54/100
📈 Last Week’s Biggest Gainers
- MRNA +176.97% (volume 26.9x average)
- AMLX +63.84% (volume 14.1x average)
- TEM +24.09% (volume 3.7x average)
- TWST +22.64% (volume 2.0x average)
- BNTX +21.96% (volume 9.1x average)
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.